1. Westerfield J, Holcomb S, Jensen S (eds). Current Trends in Diabetes Management: A Guide for the Healthcare Professional. 7th ed. Nashville, TN: Healthways; 2008.

2. Holman RR, Paul SK, Bethel MA, Matthews DR, Neil HA. 10-year follow-up of intensive glucose control in type 2 diabetes. N Engl J Med. 2008;359(15):1577-1589.

3. Reaven PD, Emanuele NV, Wiitala WL, et al. Intensive glucose control in patients with type 2 diabetes—15-year follow-up. N Engl J Med. 2019;380:2215-2224.

4. National Institute of Diabetes and Digestive and Kidney Diseases. Diabetes Prevention Program. Available athttps://www.niddk.nih.gov/about-niddk/research-areas/diabetes/diabetes-prevention-program-dpp. Last accessed February 9, 2026.

5. Davis SN, Mann S, Briscoe VJ, Ertl AC, Tate DB. Effects of intensive therapy and antecedent hypoglycemia on counterregulatory responses to hypoglycemia in type 2 diabetes. Diabetes. 2009;58(3):701-709.

6. American Diabetes Association. Standards of care in diabetes—2026. Diabetes Care. 2026;49(Suppl 1):S1-S371.

7. Bonaventura A, Montecucco F, Dallegri F. Update on strategies limiting iatrogenic hypoglycemia. Endocr Connect. 2015;4(3):R37-R45.

8. Martorella AJ. Iatrogenic hypoglycemia in patients with type 2 diabetes: comparison of insulin analog premixes and human insulin premixes. Postgrad Med. 2011;123(4):7-16.

9. Wolfsdorf JI, Weinstein DA. Hypoglycemia in children. In: Lifshitz F (ed). Pediatric Endocrinology Volume 1: Obesity, Diabetes Mellitus, Insulin Resistance, and Hypoglycemia. 5th ed. New York, NY: Informa Healthcare; 2007: 291-328.

10. McCrimmon RJ, Sherwin RS. Hypoglycemia in type 1 diabetes. Diabetes Care. 2010;59(10):2333-2339.

11. Briscoe VJ, Davis SN. Hypoglycemia in type 1 and type 2 diabetes: physiology, pathophysiology, and management. Clin Diabetes. 2006;24(3):115-121.

12. Lee MH, Ward GM, MacIsaac RJ, et al. Mortality in people with type 1 diabetes, severe hypoglycemia, and impaired awareness of hypoglycemia referred for islet transplantation. Transplant Direct. 2018;4(11):e401.

13. Cryer PE. Hypoglycemia in type 2 diabetes. In: Goldstein BJ, Müller-Wieland D (eds). Type 2 Diabetes Principles and Practice. 2nd ed. New York, NY: Informa Healthcare; 2008: 227-236.

14. Hamdy O. Hypoglycemia. Available at https://emedicine.medscape.com/article/122122-overview#a1. Last accessed February 9, 2026.

15. Bardsely JK, Ratner RE. Pathophysiology of the metabolic disorder. In: Mensing C (ed). The Art and Science of Diabetes Self-Management Education: A Desk Reference for Healthcare Professionals. 3rd ed. Chicago, IL: American Association of Diabetes Educators; 2014.

16. Arbelaez AM, Powers WJ, Videen TO, Price JL, Cryer, PE. Attenuation of counterregulatory responses to recurrent hypoglycemia by active thalamic inhibition: a mechanism for hypoglycemia-associated autonomic failure. Diabetes. 2008;57(2):470-475.

17. Schneider CA, Erdman E. Acute coronary syndrome, myocardial infarction, heart failure, and stable coronary artery disease: specific consideration in diabetes. In: Goldstein BJ, Müller-Wieland D (eds). Type 2 Diabetes: Principles and Practice. 2nd ed. New York, NY: Informa Healthcare; 2008: 463-474.

18. Eise T, Hammer GD. Disorders of the adrenal medulla. In: McPhee SJ, Hammer GD (eds). Pathophysiology of Disease: An Introduction to Clinical Medicine. 7th ed. New York, NY: McGraw Hill; 2014: 319-332.

19. Cryer PE. Mechanisms of hypoglycemia-associated autonomic failure and its component syndromes in diabetes. Diabetes. 2005;54(12): 3592-3601.

20. Fioramonti X, Fakira K, Beluch N, et al. Role of Hypothalamic S-Nitrosylation in the Development of Hypoglycemia-Associated Autonomic Failure (HAAF): Insight for Therapy [abstract]. Available at https://scholarship.libraries.rutgers.edu/esploro/outputs/journalArticle/Hypothalamic-S-Nitrosylation-Contributes-to-the-Counter-Regulatory/991031666119504646. Last accessed February 9, 2026.

21. Jones TW, Porter P, Sherwin RS, et al. Decreased epinephrine responses to hypoglycemia during sleep. N Engl J Med. 1998;338(23): 1657-1662.

22. Walsh J, Roberts R. Pumping Insulin: Everything You Need for Success with a Pump and CGM. 6th ed. San Diego, CA: Torrey Pine Press; 2016.

23. Choudhary P, Davies C, Emery CJ, Heller SR. Do high fasting glucose levels suggest nocturnal hypoglycaemia. Diabet Med. 2013;30(8): 914-917.

24. Shah VN, Akturk HK, Vigers T, Pyle L, Oliver N, Klonoff DC. Relationship between daytime versus nighttime continuous glucose monitoring metrics with A1C in adults with type 1 diabetes. Diabetes Technol Ther. 2023;25(1):62-68.

25. Acciaroli G, Welsh JB, Akturk HK. Mitigation of rebound hyperglycemia with real-time continuous glucose monitoring data and predictive alerts. J Diabetes Sci Technol. 2022;16(3):677-682.

26. Choudhary P, Rickels MR, Senior PA, et al. Evidence-informed clinical practice recommendations for treatment of type 1 diabetes complicated by problematic hypoglycemia. Diabetes Care. 2015;38(6):1016-1029.

27. Davis TM, Brown SG, Jacobs IG. Determinants of severe hypoglycemia complicating type 2 diabetes: the Fremantle diabetes study.J Clin Endocrinol Metab. 2010;95:2240-2247.

28. Freeman J, Franz MJ. Medical nutrition therapy. In: Mensing C (ed). The Art and Science of Diabetes Self-Management Education: A Desk Reference for Healthcare Professionals. 3rd ed. Chicago, IL: American Association of Diabetes Educators; 2014.

29. Spollett GR. Type 2 diabetes across the life span. In: Mensing C (ed). The Art and Science of Diabetes Self-Management Education: A Desk Reference for Healthcare Professionals. 3rd ed. Chicago, IL: American Association of Diabetes Educators; 2014.

30. de Galan BE, Zoungas S, Chalmers J. Cognitive function and risks of cardiovascular disease and hypoglycemia in patients with type 2 diabetes: the Action in Diabetes and Vascular Disease: Preterax and Diamicron Modified Release Controlled Evaluation (ADVANCE) trial. Diabetologia. 2009;52:2328-2336.

31. Seligman HK, Davis TC, Schillinger D, Wolf MS. Food insecurity is associated with hypoglycemia and poor diabetes self-management in a low-income sample with diabetes. J Health Care Poor Underserved. 2010;21:1227-1233.

32. Katon WJ, Young BA, Russo J, et al. Association of depression with increased risk of severe hypoglycemic episodes in patients with diabetes. Ann Intern Med. 2013;11(3):245-250.

33. Jou J, Johnson PJ. Nondisclosure of complementary and alternative medicine use to primary care physicians: findings from the 2012 National Health Interview Survey. JAMA Intern Med. 2016;176(4):545-546.

34. Foley H, Steel A, Cramer H, et al. Disclosure of complementary medicine use to medical providers: a systematic review and meta-analysis. Sci Rep. 2019;9:1573.

35. Egede LE, Ye X, Zheng D, Silverstein MD. The prevalence and pattern of complementary and alternative medicine use in individuals with diabetes. Diabetes Care. 2003;25(2):324-329.

36. Rhee TJ, Westberg SM, Harris IM. Complementary and alternative medicine in U.S. adults with diabetes: reasons for use and perceived benefits. J Diabetes. 2018;10(4):310-319.

37. Radwan H, Hasan H, Hamadeh R, et al. Complementary and alternative medicine use among patients with type 2 diabetes living in the United Arab Emirates. BMC Complement Med Ther. 2020;20(216)1-12.

38. Sheikhrabori A, Dehghan M, Ghaedi F, Khademi GR. complementary and alternative medicine usage and its determinant factors among diabetic patients: an Iranian case. J Evid Based Complementary Altern Med. 2017;22(3):449-454.

39. Shane-McWhorter L. Botanical dietary supplements and the treatment of diabetes: what is the evidence? Curr Diab Rep. 2005;5(5): 391-398.

40. Sisson E. AADE Quick Guide to Medications. 9th ed. Chicago, IL: American Association of Diabetes Educators; 2019.

41. Akilen R, Tsiami A, Devendra D, Robinson N. Cinnamon in glycaemic control: systematic review and meta-analysis. Clin Nutr. 2012;31(5):609-615.

42. Baker WL, Gutierrez-Williams G, White CM, Kluger J, Coleman CI. Effect of cinnamon on glucose control and lipid parameters. Diabetes Care. 2008;31(1):41-43.

43. National Center for Complementary and Alternative Medicine. Fenugreek. Available at https://nccih.nih.gov/health/fenugreek. Last accessed February 9, 2026.

44. Sasa M, Inoue I, Shinoda Y, et al. Activating effect of momordin, extract of bitter melon on the promoter of human PPARdelta.J Atheroscler Thromb. 2009;1696:888-892.

45. Joseph B, Jini D, Antidiabetic effects of Momordica charantia (bitter melon) and its medicinal potency. Asian Pac J Trop Dis. 2013;3(2):93-102.

46. National Center for Complementary and Alternative Medicine. Asian Ginseng. Available at https://nccih.nih.gov/health/asianginseng/ataglance.htm. Last accessed February 9, 2026.

47. WebMD. Prickly Pear Cactus – Uses, Side Effects, and More. Available at https://www.webmd.com/vitamins/ai/ingredientmono-880/prickly-pear-cactus. Last accessed February 9, 2026.

48. National Center for Complementary and Alternative Medicine. Aloe Vera. Available at https://nccih.nih.gov/health/aloe-vera. Last accessed February 9, 2026.

49. National Center for Complementary and Alternative Medicine. Bilberry. Available at https://nccih.nih.gov/health/bilberry. Last accessed February 9, 2026.

50. National Center for Complementary and Alternative Medicine. Milk Thistle. Available at https://nccih.nih.gov/health/milk-thistle. Last accessed February 9, 2026.

51. Mensing C. The role of the diabetes educator in the education and management of diabetes mellitus. In: Goldstein BJ, Müller-Wieland D (eds). Type 2 Diabetes: Principles and Practice. 3rd ed. New York, NY: Informa Healthcare; 2014.

52. Funk JL. Disorders of the endocrine pancreas. In: McPhee SJ, Hammer GD (eds). Pathophysiology of Disease: An Introduction to Clinical Medicine. 7th ed. New York, NY: McGraw Hill; 2014: 317-544.

53. Rx List, Inc. Amaryl. Available at https://www.rxlist.com/amaryl-drug.htm. Last accessed February 9, 2026.

54. LexiComp Online. Available at https://online.lexi.com. Last accessed February 9, 2026.

55. Pfeiffer AFH. Oral hypoglycemic agents: sulfonylureas and meglitinides. In: Goldstein BJ, Müller-Wieland D (eds). Type 2 Diabetes: Principles and Practice. 2nd ed. New York, NY: Informa Healthcare; 2008: 97-106.

56. Lipska KJ1, Warton EM, Huang ES, et al. HbA1c and risk of severe hypoglycemia in type 2 diabetes: the Diabetes and Aging Study. Diabetes Care. 2013;36(11):3535-3542.

57. Zammitt NN, Frier BM. Hypoglycemia in type 2 diabetes: pathophysiology, frequency, and effects of different treatment modalities. Diabetes Care. 2005;28(12):2948-2961.

58. Springhouse (ed). Nursing 2021 Drug Handbook. Philadelphia, PA: Lippincott, Williams & Wilkins; 2022.

59. Walsh J, Roberts R. Letter to the editor: a study that glucose control can be achieved in 31 type 1 patients who follow a controlled diet and use an insulin pump that is programmed. J Diabetes Sci Technol. 2007;1(4):L3-L6.

60. Kulkarni K. Diets do not fail: the success of medical nutrition therapy in patients with diabetes. Endocr Pract. 2006;12 (Suppl 1):121-123.

61. Healthways. Education Manual for People with Diabetes. Nashville, TN: Healthways; 2009.

62. Parsons S, Luzio S, Bain S, et al. Self-monitoring of Blood Glucose in Non-Insulin Treated Type 2 Diabetes (The SMBG Study): study protocol for a randomised controlled trial. BMC Endocr Disord. 2017;26;17:4.

63. U.S. Food and Drug Administration. FDA Approves Automated Insulin Delivery and Monitoring System for Use in Younger Pediatric Patients. Available at https://www.fda.gov/news-events/press-announcements/fda-approves-automated-insulin-delivery-and-monitoring-system-use-younger-pediatric-patients. Last accessed February 9, 2026.

64. American Diabetes Association. Continuous subcutaneous insulin infusion. Diabetes Care. 2004;27(Suppl 1):S110.

65. Schuler G, Linke A. Diabetes and exercise. In: Goldstein BJ, Müller-Wieland D (eds). Type 2 Diabetes: Principles and Practice. 2nd ed. New York, NY: Informa Healthcare; 2008: 73-82.

66. Steil CF. Pharmacological therapies for glucose management. In: Mensing C (ed). The Art and Science of Diabetes Self-Management Education: A Desk Reference for Healthcare Professionals. 3rd ed. Chicago, IL: American Association of Diabetes Educators; 2014.

67. Fowler MJ. The diabetes treatment trap: hypoglycemia. Clin Diabetes. 2011;29(1):36-39.

68. Venes D (ed). Taber's Cyclopedic Medical Dictionary. 24th ed. Philadelphia, PA: FA Davis Co.; 2021.

69. AAP News. FDA Approves 2 Products to Treat Diabetes in Pediatric Patients. Available at https://www.fda.gov/media/131381/download. Last accessed February 9, 2026.

70. Hinnen DA, Childs BP, Guthrie DW, Guthrie RA, Martin SD. Combating clinical inertia with pattern management. In: Mensing C (ed). The Art and Science of Diabetes Self-Management Education: A Desk Reference for Healthcare Professionals. 3rd ed. Chicago, IL: American Association of Diabetes Educators; 2014.

71. Davis J, Fischl AH, Beck J, et al. 2022 national standards for diabetes self-management education and support. Diabetes Care. 2022;45(2):484-494.

72. McLaughlin S. Facilitating successful self-management. In: Mensing C (ed). The Art and Science of Diabetes Self-Management Education: A Desk Reference for Healthcare Professionals. 3rd ed. Chicago, IL: American Association of Diabetes Educators; 2014.

73. Kulkarni K. Monitoring. In: Mensing C (ed). The Art and Science of Diabetes Self-Management Education: A Desk Reference for Healthcare Professionals. 3rd ed. Chicago, IL: American Association of Diabetes Educators; 2014.

74. Cryer PE. Exercise-related hypoglycemia-associated autonomic failure. Diabetes. 2009;58(9):1951-1952.

75. Banion C, Valentine V. Type 1 diabetes throughout the life span. In: Mensing C (ed). The Art and Science of Diabetes Self-Management Education: A Desk Reference for Healthcare Professionals. 3rd ed. Chicago, IL: American Association of Diabetes Educators; 2014.

76. Roberts SS. Diabetes and traffic accidents. Diabetes Self Manag. 2009:26(5):51.